Table 1. Demographics of the Development and Validation cohorts.
Development cohort n = 253 | Validation cohort n = 254 | p | |
Female | 100 (39.4%) | 100 (39.5%) | 0.97 |
Age, years | 60.1±17.6 | 60.0±17.7 | 0.92 |
Weight, kg | 79.9±18.3 | 78.4±18.4 | 0.40 |
APACHE II | 17.7±6.3 | 18.2±6.6 | 0.44 |
SOFA | 6.4±2.7 | 6.1±2.8 | 0.18 |
CKD (eGFR<60 ml/min) | 44 (17.3%) | 48 (19.0%) | 0.63 |
Sepsis | 48 (18.9%) | 48 (19.0%) | 0.98 |
Baseline plasma creatinine, mmol/L | 0.076 (0.060–0.095) | 0.075 (0.060–0.091) | 0.59 |
eGFR | 87 (67–108) | 92 (67–114) | 0.47 |
NGAL, ng/ml | 97 (32–400) | 83 (32–389) | 0.84 |
Data presented as n(%), means ± sd, or median (interquartile range). APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; CKD: Chronic Kidney Disease; eGFR: estimated Glomerular Filtration Rate using the Modification of Diet in Renal Disease (MDRD) formula.